Skip to content
Homepage
Author:
Whitehawk Therapeutics, Inc.
Posted Date:
August 6, 2026
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Whitehawk Therapeutics, Inc.
August 6, 2026
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics, Inc.
May 30, 2026
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
Whitehawk Therapeutics, Inc.
May 28, 2026
